News

Net Profit At Rs 553 Crore Vs Loss Of Rs 443 Crore (YoY)

One-Time Gain At Rs 142 Crore Vs Loss Of Rs 8 Crore (YoY)

Revenue Up 8.4% At 12019 Crore Vs 11 090 Crore (YoY)

EBITDA Up 40% At 2,205 Crore Vs 1,575 Crore (YoY)

Margin At 18.3% Vs 14.2% (YoY)

UPL Raises FY26 EBITDA Guidance To 12-16% Vs Earlier 10-14%

Revenue Growth Guidance Unchanged, Growth Seen At 4-8%

Net Profit up 23.8% At Rs 21.8 Cr Vs Rs 17.6 Cr (YoY)

Revenue down 3.1% At Rs 278.6 Cr Vs Rs 287.5 Cr (YoY)

EBITDA up 26.1% At Rs 39 Cr Vs Rs 30.95 Cr (YoY)

Margin At 14% Vs 10.8% (YoY)

Zydus Lifesciences Ltd on Tuesday reported a robust second-quarter performance for FY26, with consolidated net profit rising 39% year-on-year to ₹1,259 crore, compared with ₹911 crore in the same period last year.

The growth was supported by healthy business momentum across geographies and a sharp rise in forex gains.

The company recorded a foreign exchange gain of ₹414 crore, compared with ₹45 crore in the previous year.

here

Chola Invst Q2

Net Profit At Rs 1,155 Cr Vs CNBC-TV18 Poll Of Rs 1,170 Cr

NII At Rs 3,378 Cr Vs CNBC-TV18 Poll Of Rs 3,359 Cr

PPoP At Rs 2,458 Cr Vs CNBC-TV18 Poll Of Rs 2,482 Cr

Provisions At Rs 897 Cr Vs CNBC-TV18 Poll Of Rs 907 Cr

Net Profit up 20%  At Rs 1,155 Cr Vs Rs 963 Cr (YoY)

NII up 24.5%  At Rs 3,378 Cr Vs Rs 2,713 Cr (YoY)

Gross NPA At 5.57% Vs 4.29% (QoQ)

Board Approves Stock Split In The Ratio Of 1:5

Net Profit down 14%  At Rs 30.4 Cr Vs Rs 35.3 Cr (YoY)

Revenue up 10%  At Rs 219 Cr Vs Rs 199 Cr (YoY)

EBITDA down 2.5%  At Rs 58 Cr Vs Rs 59.4 Cr (YoY)

Margin At 26.4% Vs 29.8% (YoY)

Net Profit down 5.6% At Rs 55.4 Cr Vs Rs 58.7 Cr (YoY)

Revenue up 2.8%  At Rs 244.6 Cr Vs Rs 238 Cr (YoY)

EBITDA down 2.8%  At Rs 87.1 Cr Vs Rs 89.5 Cr (YoY)

Margin At 35.60% Vs 37.62% (YoY)

Net Profit up 2.7% At Rs 33.4 Cr Vs Rs 32.5 Cr (YoY)

Revenue up 17.8%  At Rs 968 Cr Vs Rs 822 Cr (YoY)

EBITDA up 10.3%  At Rs 85.60 Cr Vs Rs 77.60 Cr (YoY)

Margin At 8.84% Vs 9.44% (YoY)

Net profit (GU)16% at ₹415.3 crore vs ₹359 crore (YoY)

Revenue (GU)7.7% at ₹1,757 crore vs ₹1,633 crore (YoY)

EBITDA (GU)14.5% at ₹502.6 crore vs ₹439 crore (YoY)

Margin at 28.6% vs 26.9% (YoY)

Net loss at ₹64.4 crore vs loss of ₹54.2 crore (YoY)

Revenue (RD)12% at ₹494.8 crore vs ₹562.6 crore (YoY)

EBITDA (RD)7% at ₹14.8 crore vs ₹16 crore (YoY)

Margin at 3% vs 2.8% (YoY)

Net profit (GU)38% at ₹1,259 crore vs ₹911 crore (YoY)

Revenue (GU)17% at ₹6,123 crore vs ₹5,237 crore (YoY)

EBITDA (GU)38% at ₹2,014 crore vs ₹ 1,462 crore (YoY)

Margin at 32.9% vs 27.9% (YoY)

Forex gain at ₹414 crore vs gain of ₹45 crore (YoY)

Shares of Indoco Remedies Ltd. gained on Thursday, November 6, after the company witnessed a slight improvement in earnings in the second quarter.

The company’s net loss improved to ₹8 crore from ₹9.6 crore in the September quarter last year.

here

Shares of Symphony Ltd. fell as much as 7% on Thursday, November 6, in response to its results for the September quarter, which were lower on a year-on-year basis across parameters.

The company’s net profit fell 66% from last year to ₹19 crore. The company had reported a net profit of ₹56 crore during the same quarter last year.

here

The company’s net loss at the end of the September quarter narrowed to ₹418 crore from a net loss of ₹495 crore it reported during the same quarter last year. Estimates from Kotak Institutional Equities had pegged the loss to narrow further to ₹346 crore.

It has also cut its revenue and margin guidance for the full year.

here

Net Loss At Rs 21.8 Cr Vs Profit Of Rs 0.02 Cr (YoY)

Revenue up 12.7% At Rs 1,376.7 Cr Vs Rs 1,222 Cr (YoY)

EBITDA down 1.8% At Rs 192 Cr Vs Rs 196 Cr (YoY)

Margin At 14% Vs 16% (YoY)

Sun Pharma To CNBC-TV18:

Business Has Been Consistently Growing Over The Past Few Years

Focusing On Brands In India

Continue To Focus On Therapies Which The Company Has Identified

Expect To Grow Better Than The Industry

Expect Traction To Continue Going Forward

Expect Innovative Medicine Biz To Grow In The Mid-teens

Expect R&D Spend To Be At Near 6% For FY26

The stock is curretly down 7.3%.

Symphony Q2:

Net Profit down 66% At Rs 19 Cr Vs Rs 56 Cr (YoY)

Revenue down 44% At Rs 163 Cr Vs Rs 289 Cr (YoY)

EBITDA down 69% At Rs 24 Cr Vs Rs 77 Cr (YoY)

Margin At 15% Vs 26.6 (YoY)

Shares of Blue Star fell over 6% on Thursday, November 6, after the management cut its full year revenue growth guidance to flat from the earlier projection of 5%.

The management during its earnings call highlighted that the festive season has not gone well despite the reduction in the GST rates for the consumer durables like Room Air-Conditioners.

here

– Booking Value Up 64% YoY & 20% QoQ To ₹8,505 Crore

– Achieved 48% Of Annual Guidance For Booking Value In H1FY26

– Remains On Track To Beat Guidance Of ₹32,500 Crore Booking Value For FY26

– Collections Up 2% YoY & 11% QoQ  To ₹4,066 Crore

– Area Sold Up 39% YoY & 16% QoQ At 7.14 million square feet

Net Profit Up 21% At 405 Vs Rs 335 Crore

Revenue Down 32% At 740 Crore 1093 Crore

EBITDA Loss At Rs 513 Crore Vs EBITDA Of Rs 32 Crore

FY26 revenue growth target cut to flat Vs earlier target of 5% growth

Upper end growth target of UCP segment cut, now seen at 7-7.5%

Blue Star Says | From Concall:

Q2 Was A Tough Qtr, Unseasonal Rains & Delay In GST Cut Impacted Performance

Believe H2 Will Be Better Than H1, But Doubt It Will Make Up For The Loss

FY26 Will Likely See A Flat Growth On A YoY Basis

RAC Industry Likely To See Decline Of 15% YoY This Year

Saw More Than Of 35% Sales From Sep 22 Till Diwali

Tariff Related Uncertainties Still Persist

There Is No Doubt About Long-term Growth Prospects Of Co

Fundamentals Continue To Remain Strong, Growth Momentum Continues

SRF To CNBC-TV18:

Tariffs Have Created A Lot Of Uncertainty In The System

Tariffs Really Hit Us Badly

There Is No Doubt That For The Last 3 Months Exports Of The US Have Been Impacted

China Added A Lot Of Capacity Post COVID Across Various Sectors

China Wants To Grab Market Share Everywhere

Companies Like Us Have To Find Niche Areas Of Being Able To Compete With China

One Of The Sectors That We Supply To In The Speciality Chemicals Business Is The Agrochem Sector

Agrochem Sector Has Been Hit Badly By Tariffs

Recovery In Agrochem Is Going To Take Longer Than What We Anticipated

We Are Seeing A Lot More Traction On The Refrigerant Gas Side

Growth Is Largely Going To Come From The Chemicals Sector

Revenue up 12%At Rs 485 Cr Vs Rs 433 Cr (YoY)

EBITDA up 6.6%At Rs 43.4 Cr Vs Rs 41 Cr (YoY)

Margin At 9% Vs 9.4% (YoY)

Net Loss At Rs 8 Cr Vs Loss Of Rs 9.6 Cr (YoY)

Shares of Epack Durables Ltd. fell over 10% on Thursday, November 6, in response to its September quarter results, where the company’s losses widened for the quarter from last year.

The company’s net loss for the quarter widened to ₹8.5 crore from a loss of 6.1 crore it reported during the same quarter last year. This is despite a significant jump in other income to ₹4.7 crore from ₹70 lakh last year.

here

Shares of Redington Ltd. surged over 12% on Thursday, November 6, after the company reported strong year-on-year growth and a sharp sequential improvement in performance. Margins remained stable at around 2%.

The Software Solutions Group (SSG) posted a 48% year-on-year increase, driven by sustained momentum in cloud, software, and cybersecurity. The Mobility Solutions Group (MSG) grew 18% year-on-year, driven by higher demand in the premium smartphone segment, new product introductions, and robust execution under its Direct-to-Retail model.

here

Redington On CNBC-TV18:

PC Business Saw A Double-digit Growth In Q2FY26 & Expect Momentum To Continue

Outlook Is Positive & All Geographies Are Seeing Good Tech Growth

Maintain The Margin Guidance Of 2.3-2.5% (Ex-Arena)

SSG is a high margin business and now accounts to 16% of the rev vs 15% last year

Exited From The Vodafone Business In Turkey & Will Take 3-4 Months For Full Exit

Expect Software & Tech Solution Business To Increase In Q3 & Q4 From Current 35%

The stock is currently down 2.2%.

The company’s net profit for the quarter under review increased 102% to ₹121.4 crore from ₹60.2 crore in the same period last year.

Its revenue was up 58.4% at ₹906.2 crore from ₹572 crore in the second quarter last fiscal.

here

Kedar Lele, Castrol India On CNBC-TV18:

Have Delivered Profitability & Volume Growth

Volume Growth In High Single-digit

EBITDA Margin In The 21–23% Range

FY26 Has Been Very Tough Due To Weakness Vs USD

Announced MoU With Vietnamese EV Company, Will Provide After-sales Services For Them

We Are Waiting For A Decision On BP’s Stake In Castrol

Ola Elec Guidance Cut

FY26 Rev Now Seen At Rs 3,000-3,200 Cr Vs Rs 4,200-4,700 Cr Earlier

FY26 Auto Margin Now Seen Around 5% Vs Earlier Tgt Of Above 5%

Indian Metals On CNBC-TV18:

Have Announced Acquisition Of Tata Steel Unit

Base Consideration Of Rs 610 Cr, Plus GST Consideration, We Will Get Input Tax Credit

Will Need To Make An Outlay Of Rs 50 Cr Additionally

Will Meet All Chrome Ore Requirements From Captive Mines

Steady-State Production Is 260,000 Tonnes

EBITDA Is A Function Of Selling Price As Well As Costing

Steady-State EBITDA In The Range Of Rs 18,000–20,000 CrNewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.